U.S. markets closed
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow 30

    34,899.34
    -905.06 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.54 (-2.23%)
     
  • Russell 2000

    2,245.94
    -85.52 (-3.67%)
     
  • Crude Oil

    68.17
    -10.22 (-13.04%)
     
  • Gold

    1,792.30
    +8.00 (+0.45%)
     
  • Silver

    23.15
    -0.35 (-1.49%)
     
  • EUR/USD

    1.1326
    +0.0114 (+1.02%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • GBP/USD

    1.3326
    +0.0006 (+0.05%)
     
  • USD/JPY

    113.4970
    -1.8420 (-1.60%)
     
  • BTC-USD

    54,734.05
    -338.66 (-0.61%)
     
  • CMC Crypto 200

    1,365.60
    -89.81 (-6.17%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • Nikkei 225

    28,751.62
    -747.68 (-2.53%)
     

Protagonist Therapeutics Announces Pricing of $115 Million Upsized Public Offering of Common Stock

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEWARK, Calif., June 15, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 3,046,358 shares of its common stock at a price to the public of $37.75 per share. Gross proceeds to Protagonist from the offering are expected to be approximately $115 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Protagonist. In connection with this offering, Protagonist has granted the underwriters a 30-day option to purchase up to 456,953 additional shares of its common stock at the public offering price less underwriting discounts and commissions.

J.P. Morgan Securities LLC, Jefferies LLC and Piper Sandler are acting as joint book-running managers for the offering. JMP Securities LLC and H.C. Wainwright & Co., LLC are acting as co-lead managers for the offering. The offering is expected to close on or about June 18, 2021, subject to satisfaction of customary closing conditions.

A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC) on December 10, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and a final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website, located at www.sec.gov. The offering is being made only by means of a prospectus supplement and accompanying prospectus. Copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at 866-803-9204, or by email at prospectus-eq_fi@jpmchase.com; Jefferies LLC (Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022; telephone: 877-821-7388; email: Prospectus_Department@Jefferies.com); or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients. Protagonist is headquartered in Newark, California.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Protagonist's expectations regarding the completion and timing of the public offering. In some cases, you can identify these statements by forward-looking words such as "expect," "may," "will," or the negative or plural of these words or similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). These forward-looking statements are based on Protagonist's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering. There can be no assurance that Protagonist will be able to complete the public offering on the anticipated terms, or at all. Additional information concerning these and other risks can be found in Protagonist's periodic filings with the SEC, including under the heading "Risk Factors" contained therein, as well as the risks identified in the registration statement and the preliminary prospectus supplement relating to the offering. Any forward-looking statements that Protagonist makes in this press release speak only as of the date of this press release. Except as required by law, Protagonist assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)
Protagonist Therapeutics, Inc. (PRNewsFoto/Protagonist Therapeutics, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-pricing-of-115-million-upsized-public-offering-of-common-stock-301313242.html

SOURCE Protagonist Therapeutics, Inc.